You are here
Disease modifying therapies
Distribution-based estimates of minimum clinically important difference in cognition, arm function and lower body function after slow release-fampridine treatment of patients with multiple sclerosis
H.B. Jensen, Sepehr Mamoei, M. Ravnborg, U. Dalgas, E. Stenager
Multiple Sclerosis and Related Disorders, Volume 7, May 2016, Pages 58–60
- Data from recently completed clinical trials were presented at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), held June 1-4 in National Harbor, MD. Patients of African-American descent typically experience a more-aggressive disease course of MS compared with Caucasians discussed Annette Okai...
- There is little information on the performance of disease-modifying drugs (DMDs) in the real world, according to Chris Kozma, an independent research consultant, Saint Helena Island, SC. Real world assessment of relapse rates of patients with MS comparing relapse rates between newer oral disease-modifying drugs (DMDs)...
Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis
Jordi Río, Juan Luís Ruiz-Peña
Journal of the Neurological Sciences, February 2016, Pages 158 - 167
I. Correia, S. Batista, I.B. Marques, M. Sousa, R. Ferreira, C. Nunes, M.C. Macário, L. Sousa
Multiple Sclerosis and Related Disorders, Volume 6, March 2016, Pages 41-48
Santiago Fernández-Menéndez, Marta Fernández-Morán, Iván Fernández-Vega, Angel Pérez-Álvarez, Javier Villafani-Echazú
Journal of the Neurological Sciences, Volume 361, 15 February 2016, Pages 213-219
Subcutaneous interferon β-1a in pediatric patients with multiple sclerosis: Regional differences in clinical features, disease management, and treatment outcomes in an international retrospective study
Lauren B. Krupp, Daniela Pohl, Angelo Ghezzi, Alexey Boyko, Silvia Tenembaum, Liang Chen, Ernesto Aycardi, Brenda Banwell, on behalf of the REPLAY Study Group.
Journal of the Neurological Sciences
Currently Approved And Emerging Oral Therapies In Multiple Sclerosis: An Update For The OphthalmologistSurvey of Ophthalmology, Volume 61, Issue 3, May–June 2016, Pages 318–332
Joanne Topping, Ruth Dobson, Sergey Lapin, Alexey Maslyanskiy, Harald Kropshofer, David Leppert, Gavin Giovannoni, Evgeniy Evdoshenko
Multiple Sclerosis and Related Disorders, Volume 6, March 2016, Pages 49–53
Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial
Glenn Phillips, Shien Guo, Randall Bender, Eva Havrdová, Irina Proskorovsky, Timothy Vollmer
Multiple Sclerosis and Related Disorders, Volume 6, March 2016, Pages 66 - 72